CRLCharles River Laboratories
We began operating in 1947 and, since then, have undergone several changes to our business structure. 10-K, Item 1
- Employees
- 19,700
- Headquarters
- Wilmington, MA
- CEO
- Birgit Girshick
- Next results
- around Jan 12, 2027
Key numbers
Latest fiscal year, with ten years behind eachWhat changed
10-K filed Feb 18, 2026 against Feb 19, 2025| Area | What changed | Source |
|---|---|---|
| Risk factors | 21 new paragraphs, nothing like them in the previous 10-K | 10-K Item 1A |
| Accounting checks | 11 other checks clear | 10-K · XBRL |
| Insiders | 1 open-market buy in the last 90 days | Form 4 |
| Filings | 3 in the last 30 days | EDGAR |
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
What's new, in their words
10-K filed Feb 18, 2026Paragraphs in Risk Factors that were not in the 10-K filed 2025-02-19. Quoted as filed.
We leverage software and hardware solutions from technology and services providers, including software-as-a-service and public cloud infrastructure, who have been subject to cybersecurity incidents in the past and may have incidents or breaches in the future. As of the date of this filing, to our knowledge, no prior cybersecurity…
10-K, Item 1A
Accounting checks
latest 10-K11 of 11 clear 0 worth a look. Checks, not verdicts.
- ✓Receivables -1.7% vs revenue -0.9% (-0.8 pts)
- ✓Cash from operations $737.6M vs net income −$144.3M (FY ending 2025-12-27)
- ✓Inventory +7.4% vs revenue -0.9% (+8.2 pts)
- ✓Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
- ✓No statement of substantial doubt about going concern
- ✓No 8-K item 4.02 in the last 2 years
- ✓No NT 10-K or NT 10-Q in the last 2 years
- ✓The same matters as last year: Annual Goodwill Impairment Assessment - Biologics Solutions Reporting Unit; Revenue Recognition using the Cost-to-Cost Method - Discovery and Safety Assessment
- ✓No sentence in the 10-K concludes that controls were not effective because of a material weakness
- ✓No 8-K item 2.06 in the last 2 years
- ✓No 8-K item 1.03 in the last 2 years
In the last 30 days
All filings →- Nov 9, 20268-K Regulation FD disclosure 8-K item 7.01
- Nov 4, 20268-K Quarterly results 8-K item 2.02
- Nov 4, 202610-Q Quarterly report (10-Q) period ended Sep 26, 2026
About Charles River Laboratories
10-K, Feb 18, 2026We began operating in 1947 and, since then, have undergone several changes to our business structure. Charles River Laboratories International, Inc. was incorporated in 1994 and we completed our initial public offering in 2000. Our stock is traded on the New York Stock Exchange under the symbol “CRL” and is included in the Standard & Poor’s 500 and Composite 1500 indices, the New York Stock Exchange (NYSE) Arca Biotechnology Index, the NYSE Composite and many of the Russell indices, among others. We are headquartered in Wilmington, Massachusetts. Our headquarters mailing address is 251 Ballardvale Street, Wilmington, MA, 01887, and the telephone number at that location is (781) 222-6000.
- Headquarters
- Wilmington, MA
- Country
- United States
- Reports in
- USD
- Listed on
- NYSE
- Fiscal year ends
- December 27
- Last results
- Nov 4, 2026
Employees, at the top of the page: "As of December 27, 2025, we had approximately 19,700 employees (including approximately 2,400 science professionals with advanced degrees, including Ph" (10-K). Address and exchange: SEC's company file.
Permanent link, kept if the ticker changes: /c/sec:0001100682 (SEC's CIK).
Work on CRL in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/CRL/export.csv") into a cell.